Key result
Interrupted edoxaban resulted in a shorter baseline ACT (130 vs 152 seconds, P<0.0001) and required higher total heparin during AF ablation compared to uninterrupted warfarin.
Why the study?
Does interrupted edoxaban require a higher initial heparin dose compared to uninterrupted warfarin to achieve target ACT during atrial fibrillation ablation?
RCT (n=240)
Randomized (for heparin doses in edoxaban group)
Does interrupted edoxaban require a higher initial heparin dose compared to uninterrupted warfarin to achieve target ACT during atrial fibrillation ablation?
Absolute Event Rate: 130% vs 152%
p-value: p=<0.0001
Patients on interrupted edoxaban require higher initial and total heparin doses during atrial fibrillation ablation to achieve similar ACT targets compared to those on uninterrupted warfarin.
Interrupted edoxaban was associated with shorter baseline ACT than warfarin; leaves open optimal initial heparin dosing for target ACT in AF ablation.
BACKGROUND: Different target activated clotting times (ACTs) during atrial fibrillation (AF) ablation have been proposed. Moreover, relationships between initial bolus dose of heparin at the start of AF ablation in patients receiving edoxaban anticoagulation therapy and ACT are unclear. METHODS: Patients who received anticoagulation with uninterrupted warfarin (control; n = 120) or interrupted edoxaban (n = 120) on the morning of day of ablation were studied. An initial dose of 100 U/kg heparin was administered as a reliable control for warfarin. Initial heparin doses of 120, 130, 140, or 150 U/kg were randomly administered to the edoxaban group. RESULTS: Edoxaban group showed shorter baseline ACT before the procedure (130 ± 16 seconds) than the warfarin group (152 ± 26 seconds, P < 0.0001). In the warfarin group, 100 U/kg heparin showed 361 ± 48 seconds 15-minute ACT. In the edoxaban group, an increase in initial dose induced prolongation of 15-minute ACT (i.e., 15-minute ACTs of 293 ± 56, 306 ± 39, 311 ± 45, and 319 ± 45 seconds for 120, 130, 140, and 150 U/kg initial doses, respectively). The total heparin required during the procedure was higher in the edoxaban group than in the warfarin group (109 ± 37 vs. 77 ± 21 U/kg/h, P < 0.0001). The 120-150 U/kg dose of heparin in edoxaban group did not cause thromboembolic or major bleeding complications. CONCLUSION: Edoxaban interrupted on the day of ablation showed a shorter baseline ACT than uninterrupted warfarin. Edoxaban required a higher initial heparin dose to achieve a similar 15-minute ACT to warfarin. These results are useful for determining the initial heparin dose required to achieve variable target ACTs.
No takes yet. Share an insight, caveat, or question.
Yamaji et al. (2018) conducted an RCT in Atrial fibrillation (n=240). Interrupted edoxaban with variable initial heparin doses vs. Uninterrupted warfarin with 100 U/kg initial heparin was evaluated on Baseline activated clotting time (ACT) before the procedure (seconds) (p=<0.0001). Interrupted edoxaban resulted in a shorter baseline ACT (130 vs 152 seconds, P<0.0001) and required higher total heparin during AF ablation compared to uninterrupted warfarin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: